Vigil neuroscience to present at guggenheim securities smid cap biotech conference

Watertown, mass., jan. 30, 2025 (globe newswire) -- vigil neuroscience, inc. (nasdaq: vigl), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the guggenheim securities smid cap biotech conference on february 6, 2025, at 10:30 a.m. et.
SMID Ratings Summary
SMID Quant Ranking